Sutro Biopharma (STRO) Other Accumulated Expenses (2017 - 2025)

Sutro Biopharma has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $2.9 million for Q4 2025.

• Other Accumulated Expenses for Q4 2025 came in at $2.9 million, down 27.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.9 million (down 27.34% YoY), and the FY2025 annual result was $2.9 million, down 27.34% from the prior year.
• Other Accumulated Expenses came in at $2.9 million for Q4 2025 at Sutro Biopharma, down from $15.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.8 million in Q2 2025 to a low of $185000.0 in Q1 2021.
• The 5-year median for Other Accumulated Expenses is $3.4 million (2024), against an average of $5.0 million.
• Across the five-year window, Other Accumulated Expenses tumbled 91.39% in 2021 and surged 1408.11% in 2022, its largest moves.
• Sutro Biopharma's Other Accumulated Expenses stood at $2.8 million in 2021, then increased by 12.0% to $3.1 million in 2022, then increased by 26.53% to $3.9 million in 2023, then increased by 2.87% to $4.0 million in 2024, then dropped by 27.34% to $2.9 million in 2025.
• The last three Other Accumulated Expenses figures came in at $2.9 million (Q4 2025), $15.8 million (Q3 2025), and $17.8 million (Q2 2025), per Business Quant data.